The global Hematologic Malignancies Testing Market is forecasted to be worth USD 5.45 Billion by 2027, according to a current analysis by Emergen Research. The rapid growth of the global market for Hematologic Malignancies Testing can be attributed to the rising prevalence of Leukemia and Multiple myeloma. 10% of all hematologic cancers are due to multiple myeloma. It is estimated that about 12,830 deaths from multiple myeloma (7,190 in men and 5,640 in women) will happen in 2020.
The detailed market intelligence report on the Hematologic Malignancies Testing market applies the best of both primary and secondary research to weighs upon the competitive landscape and the prominent market players expected to dominate the Hematologic Malignancies Testing market for the forecast period, 2020 - 2027. The study not only scans through the company profile of the major vendors but also analyses their winning strategies to give business owners, stakeholders and field marketing personnel a competitive edge over others operating in the same space. A detailed evaluation of the major events such as acquisition and mergers, collaborations, product launches, new entrants, and technology advancements offer a complete overview of what the future of the Hematologic Malignancies Testing market will be like in the years to come.
Besides, increasing awareness among patients and healthcare professionals about the initial diagnosis of Hematologic Malignancies is anticipated to stimulate growth over the forecasted timeframe. Furthermore, the rising emphasis on personalized medicine is also expected to drive the market growth of global Hematologic Malignancies Testing. This procedure can be used in a very particular way to identify and diagnose disorders, classifying those through hereditary variance instead of by symptoms. This encourages more precise and efficient therapies, strengthening the prognosis of patients.
Read more@ https://www.emergenresearch.com/industry-report/hematologic-malignancies-testing-market.
Key Highlights From The Report
In March 2020, Sysmex Corporation received japan marketing clearance for BGI Genomics Coronavirus kit distribution. This initiative will strengthen its position in Japan.
During the forecast timeline, the Next-generation sequencing segment will hold the largest market with a CAGR of 14.8%. In next-generation sequencing, the steadily developing cohort of technologies allowing the detection of gene variations present in Rna and DNA. In the case of hematologic malignancies, such differences provide diagnostic relevance.
It is expected that the Leukemia segment will hold the largest market throughout the forecasted period. The demand for early diagnosis and growing the cases of leukemia are expected to drive the growth of this segment.
The region of North America accounts for the largest market in the forecast timeline. The presence of the key players, and the existing advanced healthcare facilities, are the forces responsible for growth.
Key participants include ArcherDx, Inc., Bio-Rad Laboratories, Inc., Sysmex Corporation, Invitae Corporation, NeoGenomics Laboratories, Inc., Abbott Laboratories, Cancer Genetics Inc., Adaptive Biotechnologies Corporation, Asuragen, Inc., and Invivoscribe, Inc. among others.
Request For Free Sample@ https://www.emergenresearch.com/request-sample/368
Product Outlook (Revenue, USD Billion; 2017-2027)
Services
Kits
Technology Outlook (Revenue, USD Billion; 2017-2027)
Polymerase Chain Reaction
Immunohistochemistry
Next-generation sequencing
Fluorescence in situ hybridization
Disease Outlook (Revenue, USD Billion; 2017-2027)
Multiple myeloma
Myelodysplastic syndrome
Leukemia
Myeloproliferative neoplasms
Lymphoma
End-Use Outlook (Revenue, USD Billion; 2017-2027)
Research Institutions
Hospitals
Specialty Clinics
Laboratories
Regional Outlook (Revenue, USD Billion; 2017-2027)
North America
Europe
Asia Pacific
Latin America
MEA
Table of Content
Chapter 1. Methodology & Sources
1.1. Hematologic Malignancies Testing Market Definition
1.2. Hematologic Malignancies Testing Market Research Scope
1.3. Hematologic Malignancies Testing Market Methodology
1.4. Hematologic Malignancies Testing Market Research Sources
1.4.1. Primary
1.4.2. Secondary
1.4.3. Paid Sources
1.5. Hematologic Malignancies Testing Market Estimation Technique
Chapter 2. Executive Summary
2.1. Summary Snapshot, 2019-2027
Chapter 3. Key Insights
Chapter 4. Hematologic Malignancies Testing Market Segmentation & Impact Analysis
Continued…
